Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (GB:0HF9)
LSE:0HF9
Amicus (0HF9) Share Price & Analysis
0 Followers
0HF9 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.74 - $14.57
Previous Close$10.54
Volume0.00
Average Volume (3M)483.00
Market Cap
$3.12B
Enterprise Value$3.29B
Total Cash (Recent Filing)$280.30M
Total Debt (Recent Filing)$454.29M
Price to Earnings (P/E)N/A
Beta0.82
Next Earnings
May 07, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding295,382,614
10 Day Avg. Volume661
30 Day Avg. Volume483
Standard Deviation0.16
R-Squared0.13
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-53.66
Price to Sales (P/S)17.24
Price to Cash Flow (P/CF)225.50
P/FCF Ratio50.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.84
Enterprise Value/Gross Profit11.32
Enterprise Value/Ebitda-27.38
Forecast
1Y Price Target
$17.80Price Target Upside68.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Amicus News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's goal of >$500M in total revenue in 2024 is seen as a milestone, emphasizing their growth potential.
Market DemandAn increasing rate of patient adds at the start of the year suggests a strengthening market demand for the company's therapies.
Product Launch SuccessThe Pombiliti/Opfolda launch is progressing well with approximately 120 patients on treatment, indicating strong early adoption.
Bears Say
Company GuidanceInvestors are showing concern over the company's guidance, which has caused a decrease in the stock price.
Drug Revenue GuidanceNo revenue guidance was provided for Pombiliti/Opfolda for 2024, which may be seen as a disappointment despite understanding the caution due to early launch stages.
Growth OutlookThe company expects growth to marginally slow down in 2024.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.09% Other Institutional Investors
99.91% Public Companies and
Individual Investors
0HF9 FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest share price was $9.74 and its highest was $14.57 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Currently, no data Available
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Feb 28, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.058 by -$0.052.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Amicus Therapeutics have?
Currently, no data Available
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.058. Following the earnings report the stock price went down -7.74%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Among the largest hedge funds holding Amicus Therapeutics’s share is Perceptive Advisors LLC. It holds Amicus Therapeutics’s shares valued at 398M.
---
Amicus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.80 (68.88% Upside)
$17.80 (68.88% Upside)
Blogger Sentiment
Bullish
GB:0HF9 Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $84.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.12%
12-Months-Change
Fundamentals
Return on Equity
-107.04%
Trailing 12-Months
Asset Growth
7.42%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
---
0HF9 Company Deck
---
0HF9 Earnings Call
Q4 2024
0:00 / 0:00
---
0HF9 Stock 12 Months Forecast
Average Price Target
$17.80
▲(68.88% Upside)
Technical Analysis
Amicus
―
Sarepta Therapeutics
―
SAGE Therapeutics
―
Bioline RX Ltd Sponsored ADR
―
ANI Pharmaceuticals
―
Best Analysts Covering 0HF9
1 Year
1 Year Success Rate
12/23 ratings generated profit
1 Year Average Return
+19.22%
reiterated a buy rating last month
Copying Anupam Rama's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +19.22% per trade.
---